Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 900
- Avg volume
- —
- Day's range
- $1.67 – $1.67
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule...
Show more
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 236 516 7714
- Website
- https://www.metherapeutics.com
- Address
- 177 Robson Street, Vancouver, Canada
Latest news
No headlines yet.
